Nexviadyme (Avalglucosidase Alfa)

Avalglucosidase alfa is a recombinant form of the human enzyme acid alpha‑glucosidase. After intravenous infusion, it is taken up by lysosomes via mannose‑6‑phosphate receptors, where it hydrolyzes stored glycogen into glucose, thereby decreasing glycogen overload and improving muscle function.

The dosing regimen for Nexviadyme is individualized. The prescribing physician determines the appropriate dose, infusion rate, and frequency based on the patient’s age, weight, disease severity, and clinical response.

Safety data for Avalglucosidase alfa in pregnancy and lactation are limited. Clinicians should weigh potential benefits against unknown risks and discuss these considerations with the patient before initiating therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Nexviadyme provides recombinant acid alpha‑glucosidase similar to other enzyme replacement products, but differences may exist in manufacturing process, glycosylation patterns, and infusion protocols. Clinical outcomes and safety profiles should be compared on a case‑by‑case basis under specialist guidance.

Nexviadyme must be stored refrigerated between 2 °C and 8 °C, protected from light, and should never be frozen or shaken. Prior to infusion, the product should be inspected for particulate matter and used within the manufacturer‑specified time window.

The medication is given as an intravenous infusion under the supervision of a qualified healthcare professional. Infusion duration and rate are determined by the prescriber, and patients are monitored for infusion‑related reactions throughout the procedure.

Serious adverse events include anaphylaxis, severe hypersensitivity reactions, cardiac arrhythmias, and significant respiratory compromise during infusion. Prompt recognition and management of these events are essential, and patients should be observed closely during and after administration.

Nexviadyme is contraindicated in patients with a known hypersensitivity to Avalglucosidase alfa or any of its excipients. Caution is also advised for individuals with uncontrolled cardiac or severe respiratory conditions, and for those receiving live vaccines.